Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine for left ventricular hypertrophy in diabetic nephropathy with stage IV chronic kidney disease
ACTRN12610000779077Phase 4Completed
- Sponsor
- Escuela Superior de Medicina del Instituto Politécnico Nacional
- Start
- Nov 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in left ventricular hypertrophy (LVH), diabetic glomerulosclerosis, chronic kidney disease (CKD) and 1 more comparing Bromocriptine plus current treatment with Placebo plus current treatment (2 arms). Primary endpoints: Change in left ventricular hypertrophy and Change in ambulatory blood pressure. Started Nov 2004; status: completed.
02
Drugs
bromocriptine
03
Conditions
left ventricular hypertrophy (LVH)diabetic glomerulosclerosischronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12610000779077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000779077.